Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Dividends Calendar
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team
Pressemeddelelse

Alligator Bioscience: BioStock: Alligator's CEO on current development and the rights issue

Alligator Bioscience

Alligator Bioscience got off to a turbocharged 2023 by presenting positive interim results from the phase II OPTIMIZE-1 study with mitazalimab in pancreatic cancer, and the company has continued to deliver positive news during Q1. Now, the company is carrying out a rights issue of approximately 199 MSEK to advance the study even further, among other things. BioStock talked to CEO Søren Bregenholt to discuss the purpose of the rights issue in more depth.

Read the interview with Søren Bregenholt at biostock.se:

https://www.biostock.se/en/2023/05/alligators-ceo-on-current-development-and-the-rights-issue/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.
  • Latest
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Dividends Calendar
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team